2009 Medical Innovation Summit Agenda
JUMP TO :
October 5, 2009 |
October 6, 2009 |
October 7, 2009
|
MONDAY, OCTOBER 5, 2009
|
2:00 - 2:05 P.M. |
Welcome
Delos Cosgrove, MD
Chief Executive Officer and President
Cleveland Clinic
|
2:05 - 2:20 P.M. |
New Technology in Cancer - Key Issues: Summit Overview
Derek Raghavan, MD, PhD
Chair and Director, Taussig Cancer Institute, Cleveland Clinic
Dr. Raghavan, drawing on his leadership role at the nexus of clinical care and discovery
science, will highlight the issues behind the topics that will be covered during the
Summit.
Perspectives from the Top of the Industry
Moderator: Roger Longman
Managing Director, Pharma, Elsevier Business Intellegence
|
2:20 - 2:50 P.M. |
David Brennan
Chief Executive Officer, AstraZeneca
Mr. Brennan is both CEO of AstraZeneca and current Chairman of the Pharmaceutical Research and
Manufacturers Association (PhRMA). Under Brennan's leadership, AstraZeneca has significantly
advanced as a global leader in the war against cancer and he has expanded AstraZeneca's capabilities
into new areas of technology. Arimidex is a market leader for breast cancer therapy and
AstraZeneca's acquisition of MedImmune positions the company to assert its biologics expertise.
|
3:00 - 3:45 P.M. |
Dan Vasella, MD
Chief Executive Officer, Novartis
Dr. Vasella has been CEO of Novartis since the merger that created the company in 1996.
He is leading an organization with a vibrant research and development program and has overseen
the building of one of the largest oncology pipelines in the industry. Novartis' introduction of Gleevec
in 2001 marked the entry of the first tyrosine kinase inhibitor and set the standard for the prototypical
targeted cancer therapy. Gleevec is one of the Top 10 biologic drugs with annual revenues of
$3.7 billion.
|
3:45 - 5:30 P.M. |
The Grand Challenges in Contemporary Cancer Treatment and Biology
Moderator: Derek Raghavan, MD, PhD
Leaders from multiple fronts in the war on cancer will reflect on the great challenges in treatment
and molecular prognostication of cancer and the prospects for meaningful progress in those areas
in the next decade.
- William Hait, MD, PhD
Senior Vice President, Worldwide Head, Hematology and Oncology, Johnson & Johnson
- Tom Miller
Chief Executive Officer, Workflow Solutions, Siemens
- Sir Bruce Ponder, MD, PhD
Director, Cancer Research UK Cambridge Research Institute
Download Presentation
- Kári Stefánsson, MD
Chief Executive Officer, deCODE genetics
|
6:30 - 10:00 P.M. |
Opening Reception, Dinner and Entertainment
Cleveland Museum of Art - New Gallery Wing |
|
TUESDAY, OCTOBER 6, 2009
Back to Top
|
7:00 A.M. |
Welcome
Chris Coburn
Executive Director, Cleveland Clinic Innovations
|
7:00 - 8:00 A.M. |
Live Surgery: Robotic-Assisted Partial and Single Port Complete Kidney Removal
Moderator: Amr Fergany, MD
Staff, Glickman Urological and Kidney Institute
Surgeon: Jihad Kaouk, MD
Director, Center for Robotic Surgery, Department of Urology,
Glickman Urological and Kidney Institute, Cleveland Clinic
A partial nephrectomy will be demonstrated using the daVinci robotic surgical assistant. This
procedure will detail the challenges inherent in a partial nephrectomy and the benefit of using
robotic assistance.
|
7:00 - 8:00 A.M. |
Guided Tour
Taussig Cancer Institute - 3rd Floor Registration Desk
|
8:00 - 9:30 A.M. |
The Market for Consumer Genotyping in Oncogenomics
Moderator: Charis Eng, MD, PhD
Chair and Director, Genomic Medicine Institute, Cleveland Clinic.
Download Presentation
Few recent breakthroughs in health care have received the attention that genomic testing has. Top
leaders from throughout this emerging industry will discuss the prospects for it as a meaningful tool
for clinicians and patients in the coming years.
- Greg Lucier
Chief Executive Officer, Life Technologies
- Edward McCabe, MD, PhD
President, American Society of Human Genetics
Download Presentation
- Wayne Rosenkrans, Jr., PhD
Chief Executive Officer, Personalized Medicine Coalition
- Dietrich Stephan, PhD
Co-Founder & Chief Scientific Officer, Navigenics
- Anne Wojcicki
Co-Founder, 23 and Me
|
9:30 - 10:30 A.M. |
Innovation, IT and Health Care - The Time Has Come:
Achieving the Promised ROI in an Era of Systemic Change
Introduction by Martin Harris, MD, Chief Information Officer, Cleveland Clinic
Sam Palmisano
Chief Executive Officer, IBM
The CEO of the world's largest IT company will provide his unique perspective on the state of health
care IT. He will discuss its impact on all aspects of the health care industry and the prospects for
achieving its long sought promise for better outcomes, greater efficiency and previously unachievable
medical innovations. IBM is the largest U.S. holder of intellectual property in the world, with well
over 3,000 patents and its former top IP Counsel is the new head of the US PTO.
|
10:50 - 11:50 A.M. |
The Revolution in Radiotherapy Technology
Moderator: John Suh, MD
Chair Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic
Download Presentation
A quiet revolution has been taking place in the use of radiation technology to treat cancer. Chief
executives from throughout the industry will discuss why, what's new, and where the technology is
headed.
|
12:00 - 1:30 P.M. |
Lunch: Founder's Ballroom
Moderator: Maria Bartiromo
Anchor, CNBC
Fred Hassan
Chief Executive Officer, Schering-Plough
One of the top business correspondents and a major pharmaceutical CEO widely recognized for the high
quality of his innovation pipeline will have an insider's discussion on how the industry is changing,
the challenges to innovation-including the decline in new drug approvals-and the prospects for
future innovation in an era of reform and consolidation. Mr. Hassan's position as an architect of the
modern pharmaceutical industry was highlighted by the recent merger of Schering-Plough with Merck.
|
1:30 - 2:45 P.M. |
Corporate Venturing in a Time of Innovation and Capital Shortfalls
Moderator: Maria Bartiromo
Many large health care players have established captive venture funds. This panel of corporate and
venture leaders, moderated by Maria Bartiromo, will examine the success of the model, its current
challenges, and how it affects the development of new technology.
- Darren Carroll
Vice President, New Ventures Division, Eli Lilly
- Roy Davis
President, Johnson & Johnson Development Corporation
- Ven Manda
Vice President, Medtronic Ventures and New Therapies
- Harry Rein
General Partner, Foundation Medical Partners
- Mark Vachon
President and Chief Executive Officer, Americas, GE Healthcare
|
2:45 - 4:00 P.M. |
Maximizing Innovation in Pharma: Go It Alone, Collaborate or Acquire?
Moderator: Robert Langreth
Forbes
As the innovation mandate grows throughout the medical products industry, some companies have
responded by enhancing internal capabilities while others have found innovation through collaboration
and acquisition. This select panel of CEOs representing leading biotechnology, pharmaceutical, life
science tools, and diagnostic companies, debates the current merits of the different approaches.
|
4:00 - 5:30 P.M. |
Cooking Demonstration and Panel Discussion - Six Continents
Moderator: Michael Roizen, MD
Chief Wellness Officer, Cleveland Clinic
Eric Ziebold
Executive Chef, CityZen, Mandarin Oriental
Improving the quality of dietary intake is at the front lines of public health, cost control and disease
management. One of America's top chefs and the Clinic's own wellness czar demonstrate how
"healthful" and "delicious" can describe the same dish.
Respondents
-
William Barum
Senior Director, Operational Support Services, Cleveland Clinic
-
Steve Schimoler
Chef and Partner, Crop Bistro & Bar
|
5:00 - 7:00 P.M. |
Networking Reception and Wine Tasting - Founder's Ballroom Foyer
Marianne Frantz
American Wine School
One of America's top sommeliers will be on hand for this audience participation session on selecting
wines to complement healthful foods.
|
7:00 P.M. |
Dinner: Founder's Ballroom
Introduction by Samuel Miller, Chairman of the Board, Forest City Enterprises and Medical Mutual of Ohio
David Brooks
Columnist, New York Times
David Brooks has become one of the nation's most influential newspaper columnists. His insightful
New York Times column provides penetrating analysis and is a must-read for decision makers
throughout government and the private sector. He has recently emerged as an important voice in
the health care debate. He is also a featured commentator on "The News Hour with Jim Lehrer."
|
|
WEDNESDAY, OCTOBER 7, 2009
Back to Top
|
7:00 - 8:00 A.M. |
Live Surgery: Interstitial Thermal Therapy of a Brain Tumor
Moderator: Michael Vogelbaum, MD, PhD
Associate Director, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic
Surgeon: Gene Barnett, MD
Director, Brain Tumor and Neuro- Oncology Center, Cleveland Clinic
An aggressive brain tumor will be treated using a novel hyperthermia device within an interventional
magnetic resonance imaging scanner.
|
7:00 - 8:00 A.M. |
Guided Tour
Genomic Medicine Institute - 3rd Floor Registration Desk
|
8:00 - 9:00 A.M. |
Enabling New Technologies and New Therapies
Moderator: Ernest Borden, MD
Director, Center for Hematology and Oncology Molecular Therapies, Taussig Cancer Institute, Cleveland Clinic
This panel consisting of hands-on leaders from the industry and NIH who will examine progress
over the past five years on new targeted, biologic and chemotherapeutic agents and how they have
changed patient outcomes.
|
9:00 - 10:00 A.M. |
Meeting the Expectations of Innovation, Standards of Care and Society for New Therapies
Moderator: Ernest Borden, MD
The challenges, cost, and conduct of clinical trials and a preview of innovations to come in use of
drugs and biologics for personalized oncology and cancer prevention is the focus of this panel of
clinical, corporate, and research oncology leaders.
|
10:15 - 11:15 A.M. |
Five Ways Health Care Reform Will Change your life as an Innovator
Moderator: Debra Lappin
President, Council for American Medical Innovation
Leaders and investors at the center of the national health care debate will examine, in detail,
how issues that affect innovation at the operating level will change, including reimbursement
and product approval.
|
11:15 - 12:15 P.M. |
"Top 10" Medical Innovations for 2010
Moderator: Michael Roizen, MD
Cleveland Clinic's widely anticipated annual Top 10 medical breakthroughs will be unveiled by a
panel of the Clinic's top practitioners.
|
12:15 - 2:15 P.M. |
Lunch: Founder's Ballroom
Moderator: David Ewing Duncan
Best-Selling Author and Science Journalist
Richard Clark
Chief Executive Officer, Merck
Richard Clark will share his first-hand perspectives as one of the leaders who is reshaping the
industry and its approach to medical innovation. Under his stewardship, he has led the acquisition of
Schering-Plough and engineered a promising new anti-cancer partnership with AstraZeneca. Clark
has had a 36-year career with Merck, beginning as a quality control inspector and being chosen CEO
in 2005.
Margaret Hamburg, MD
Commissioner, US Food and Drug Administration
Few organizations affect health care innovation worldwide more than the US FDA. As President
Obama's choice to lead the FDA, Dr. Hamburg will share her vision and priorities as she guides the
agency in a period of fundamental reform and economic challenges.
|
2:15 - 2:30 P.M. |
Wrap-Up and Adjournment
Joseph Hahn, MD
Chief of Staff, Cleveland Clinic
|
2:30 - 3:30 P.M. |
Bonus Session: Meet the MDs - Individual Roundtables - Six Continents
Personalized Medicine and the Genetic Revolution - Charis Eng, MD, PhD
Innovation in Radiation Oncology- John Suh, MD
Drug Approval Process in Oncology - Derek Raghavan, MD, PhD
New Agents in Tumor Immunology - Ernest Borden, MD
Challenges in the Future of Cancer Care - Brian Bolwell, MD and Robert Dreicer, MD
|
|
